



Strathprints Institutional Repository

MacRobbie, Alison and Harrington, Gill and Bennie, Marion and Akram, Gazala and Newham, Rosemary and Corcoran, Emma Dunlop (2015) Macmillan Rural Palliative Care Pharmacist Practitioner Project Phase 2 Report January 2015. [Report] (Unpublished) ,

This version is available at <http://strathprints.strath.ac.uk/54418/>

Strathprints is designed to allow users to access the research output of the University of Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Please check the manuscript for details of any other licences that may have been applied. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (<http://strathprints.strath.ac.uk/>) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge.

Any correspondence concerning this service should be sent to Strathprints administrator: strathprints@strath.ac.uk



**WE ARE
MACMILLAN.
CANCER SUPPORT**

Macmillan Rural Palliative Care Pharmacist Practitioner Project

Phase 2 Executive Summary

January 2015



**WE ARE
MACMILLAN.
CANCER SUPPORT**



Macmillan Rural Palliative Care Pharmacist Practitioner Project

Phase 2 Executive Summary

January 2015

This work was undertaken by the
Strathclyde Institute of Pharmacy and Biomedical Sciences,
University of Strathclyde, in collaboration with NHS Highland and the Macmillan Rural
Palliative Care Pharmacist Practitioner Project Team

NHS Highland

Mrs Alison MacRobbie

Boots Company PLC

Mrs Gill Harrington

University Team

Professor Marion Bennie

Dr Gazala Akram

Dr Rosemary Newham

Mrs Emma D. Corcoran

Acknowledgements

Macmillan Cancer Support

Boots Company PLC

NHS Highland

Steering Group: Alison MacRobbie (Chair), Laura Adamu-Ikeme (Associate Development Manager NHS Highland), Linda Bailey (Care Home Manager), Cathy Brown (District Nurse, Skye), Dr Charles Crichton (GP Skye), Dr Paul Davidson (Clinical Lead/Rural Practitioner), Kate Earnshaw (District Manager), Findlay Hickey (West Operational Unit Lead Pharmacist), Pat Matheson (District Nurse Team Lead), Barbara MacDonald (Macmillan Community Nurse), Fiona MacFarlane (Boots Development Manager), Dr Leo Murray (Clinical Lead Rural Practitioner), Nancy MacAskill (Macmillan Community Nurse), Marie Noble (Care at Home Manager), Chrissan O'Halloran (Community Hospital Charge Nurse), Lis Phillips (Macmillan Community Nurse), Dr Gill Pilling (Associate Specialist, Highland Hospice), Janice Preston (Macmillan Senior Development Manager), Jean Sargeant (Macmillan Associate Development Manager), and Dr David Simes (Chair, North Skye Cancer Group), Susan Sutherland (Macmillan Development Manager North of Scotland- left post in 2013 and replaced by Joanne Adamson)

All participants of the interviews and questionnaires and those who facilitated in collecting audit data.

Executive Summary

In 2012 NHS Highland secured funding from Macmillan Cancer Support in collaboration with The Boots Company PLC to explore a new service delivery model for the rural Skye, Kyle & Lochalsh population. The project would pilot the development of a full-time Macmillan Rural Palliative Care Pharmacist Practitioner (MRPP) within in the area, and test the ability of this post to: develop community pharmacy capacity to effectively, efficiently and safely support the needs of those in this rural community with palliative care needs regardless of care setting; improve service provision/co-ordination of services ensuring opportunities are developed for training and peer support, and; provide quality information to support practice. The Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS) at the University of Strathclyde was commissioned to undertake the project evaluation.

This project is seen as a demonstration project to inform national policy with direct alignment to the objectives of the Scottish Government national action plan 'Living and Dying Well' , the Vision and Action Plan: “Prescription for Excellence” and the progressive integration of health and social care services across Scotland (1-3). The project was divided into three phases:

Phase 1 (February – December 2013)

A baseline report was produced in December 2013, focusing on the first year of project activity - specifically the investigations to characterise community pharmacy palliative care services in the project area (Skye, Kyle & Lochalsh) and to identify service gaps and key issues to inform a quality improvement programme (see Figure 1). Detailed information on the results are available in the Phase 1 report (4).

Phase 2 (January – December 2014)

Findings from Phase 1 provided the framework for Phase 2. The aims of Phase 2 were to: investigate previously unexplored areas of current service so as to provide useful recommendations for improvement; develop evidence-based resources for healthcare professionals and patients for use in the community setting, track the developments over the project duration; and provide a set of recommendations upon which the service could be developed further (Phase 3).

This report presents Phase 2 of project activity. A mixed case study approach was used, comprising questionnaires, interviews, audits and documentary data. GPs, patients, carers, Steering group members, Key Service Leads, care home staff, management and the Macmillan Rural Palliative Care

Pharmacist (MRPP) all contributed to the data. The results are summarised under two key areas: Education, Training and Awareness (Figure 2) and Integration of the MRPP in the multi-professional team (MPT, Figure 3).

Phase 3 (2015 onwards)

The results from Phase 2 were shared with the Project Steering Group to gain consensus on the prioritisation of areas for future development (Figures 4 and 5). In addition, based on the evidence gathered throughout the project and discussion with the Steering Group, a service development and sustainability model for community pharmacy palliative care services was created (Figure 6). The model, based on findings from a rural area, is designed to be flexible and applicable in a wide variety of community settings.

The model is made up of 3 steps: Start-Up, Development and Maintenance. Moving through these steps the key roles and responsibilities of the MRPP gradually shift towards the local Community Pharmacist(s), seeing the MRPP graduate from assuming a locality-based hand-on role to a more regional-based supporting and facilitating role for local champions. It was acknowledged that successful delivery of the model is dependent on alignment of resources, infrastructure and strategic and local community support.

The Audit will determine the prevalence and nature of interventions made by community pharmacy and dispensing practice staff when presented with a prescription for CDs for palliative care.

To raise the profile of the MRPP, a fortnightly drop-in clinic within Portree Pharmacy for patients/carers with palliative needs is in operation. Service users can discuss with the MRPP any issues or questions relating to medicines. The clinic was advertised and began operation in September 2013. Data is being collected on: interventions made as a result of clinic attendance; service user satisfaction; and suggestions around how the service can be improved.

The MRPP is currently attending all Gold Standards Framework Meetings in order to facilitate the future involvement of the community pharmacist in wider MPT activities. Furthermore, other healthcare professionals not previously engaged in these meetings are encouraged to attend by the MRPP.

The MRPP will devise and disseminate training materials for different members of the MPT on various pharmacy / medicines-type topics with the aim of improving the knowledge of those caring for palliative care patients. To date, the MRPP has liaised with GPs and Nursing staff in developing educational materials displaying conversion doses for opioids, anticipatory prescribing guides and guidance on correct CD prescription writing.

The possibility of developing Prescribing Clinics where patients could discuss their prescriptions and have them reassessed if necessary by an independent prescriber within the community pharmacy has been explored. This service aims to increase the profile of the community pharmacist, alerting patients to the support that the pharmacist can offer.

A need for patient education concerning opioid use was identified. This involves challenging the misconceptions surrounding opioid use within the patient and carer population.




Figure 1: Improvement Programme (Phase 1 - at Dec 2013)

FORWARD PLANNING




Figure 2: Phase 2 Education, Training & Awareness

- Attendance at, and promotion of, **Gold Standards Review Meetings**
- Community Pharmacy Palliative Care **Drop-In Clinics**
- Other clinical services:
 - **Community hospital** pharmacy work
 - **Healthcare professional queries** on medicines (dose, formulation, supply, side effects etc.) including input into Hospice Phone Line advice
 - **Patient queries** on medicines
 - **Membership of groups** including Area Pharmaceutical Committee

- **Engagement with Healthcare Professionals**
 - MRPP provided valuable information/support on medicines
 - MRPP role in care home training was recognised and seen as highly valuable
- **Engagement with Patients**
 - Direct Engagement- answering patient queries, seeing patients etc.
 - Indirect engagement- GSR meetings, imparting advice on patient care
- **MRPP Role and Service Developments**
 - Shared vs full-time MRPP role
 - Generalist vs Specialist balance of role
 - MRPP role should continue to bridge the gap between HCPs
 - MRPP should continue to provide medicines support for patients
 - MRPP role should involve training in other care settings




Figure 3: Phase 2 Integration of the MRPP in the MPT

Education, Training & Awareness

Enabling Practitioners

Care Home Staff

- **Ongoing:** The development and roll out of additional Sunny Sessions training materials
- **Ongoing:** Access to further learning resources beyond Sunny Sessions (e.g. The Current Learning in Palliative Care and the NES Pharmacy Technician training pack)
- **Phase 3:** Support staff in their knowledge of new medicines with medicines information sheets
- **Phase 3:** Explore a mechanism to make Sunny Session training a national resource.

Healthcare Professionals

- **Ongoing:** Deliver tailored GP talks on request (e.g. symptom management i.e. breathlessness, use of 'specials' etc.)
- **Ongoing:** Maintain locality group pharmacy peer-review and training development
- **Phase 3:** Improve access to all training through the use of webinars and other technology
- **Phase 3:** Facilitate local multi professional team training
- **Phase 3:** Explore potential for further distribution of the mouse mats, mugs and any other educational materials across NHS Highland
- **Phase 3:** Test the roll out of the Sunny Sessions care home training information packs to other health/social care support workers (SVQ Level 2 and 3).

Enabling Patients & Carers

- **Phase 3:** Adapt and test the roll out of Sunny Sessions training and make available to family carers, patients and members of the public through established settings (e.g. Macmillan days etc.)
- **Phase 3:** Promote further MSP visit to the project area following MSPs Dave Thomson and Rhoda Grant's visits
- **Phase 3:** Test currently developed materials i.e. "Ask 3" cards and medicines information cards
- **Phase 3:** Explore use of twitter account and hashtag to enable non-direct contact with patients (#SkyeLochPharm)
- **Phase 3:** Explore access to medicines information materials in non-clinical settings e.g. libraries.

Figure 4: Education, Training and Awareness Work Planned for Phase 3

Integration of the MRPP in the MPT

Gold Standards Review Meetings

- **Ongoing:** Attend GSR meetings to provide information and insight into palliative medication related issues in patients
- **Ongoing:** Raise issues at a local level at GSR meeting from Highland Hospice calls
- **Phase 3:** Explore how Community Pharmacists can contribute to GSR meetings through the use of technology
- **Phase 3:** Develop Top Ten Tips guide for healthcare professionals for conducting GSR Meetings.

Further Engagement Opportunities

- **Ongoing:** Raising ethical issues in the quarterly Palliative Care Model Schemes Newsletter starting Nov 2014, with feedback request & answers in next quarterly newsletter
- **Ongoing:** Provide continued advice and support to Macmillan Nurses relating to palliative care medicines
- **Phase 3:** Conduct a follow-up audit of CD prescribing
- **Phase 3:** Support Community Pharmacists across the project area in developing and hosting their own drop-in clinics, independent prescribing clinics and/or providing teach-back experience for patients' improved understanding of medicines.

Access to Patients' Medicine Information

- **Phase 3:** Implement a system where access to patient hospital admission and discharge information, including Immediate Discharge Letters (IDLs) as well as more advanced information for Community Pharmacists is arranged.

Figure 5: Integration of the MRPP in the MDT Work Planned for Phase 3




Figure 6: Service Development and Sustainability Model

Conclusions

For NHS Scotland, the evidence from this project presents for the first time, a conceptualised clinical practice model for community pharmacy palliative care services in rural areas, building upon the experiences from NHS GG&C, i.e. a highly populated urban environment (5). The model aligns with existing key health policy, namely “A Route Map to the 2020 Vision for Health and Social Care” (2), “Living & Dying Well” (3), “The Healthcare Quality Strategy” (6) and the recently published Vision and Action Plan: “Prescription for Excellence” (1). Adoption of this model will maximise community pharmacists’ professional competence in planning and delivering specialist clinical services while maintaining a generalist role. The model provides detail of the key roles and responsibilities to support the safe and effective use of medicines for patients and their carers, but provides it in a format that enables flexibility for the deployment of these functions depending on local business planning, service delivery frameworks and community setting.

References

1. Prescription for Excellence: A Vision and Action Plan: Scottish Government; 2013. Available from: <http://www.scotland.gov.uk/resource/0043/00434053.pdf>.
2. A Route Map to the 2020 Vision for Health and Social Care: Scottish Government 2013. Available from: <http://www.scotland.gov.uk/Resource/0042/00423188.pdf>.
3. Living and Dying Well: a national action plan for palliative and end of life care in Scotland Edinburgh: Scottish Government 2008. Available from: <http://www.scotland.gov.uk/resource/doc/239823/0066155.pdf>.
4. Bennie M, MacRobbie A, Akram G, Newham R, Corcoran ED, Harrington G. Macmillan Rural Palliative Care Pharmacist Practitioner Project: Mapping of the Current Service & Quality Improvement Plan University of Strathclyde, 2013.
5. Bennie M, Akram G, Corcoran ED, Maxwell D, Trundle J, Afzal N, et al. Macmillan Pharmacist Facilitator Project- Final Evaluation Report. Macmillan Cancer Support: University of Strathclyde, 2012.
6. The Healthcare Quality Strategy for NHSScotland: Scottish Government 2010. Available from: <http://www.scotland.gov.uk/Resource/Doc/311667/0098354.pdf>